Regeneron’s Promising Study on Odronextamab for B-cell Non-Hodgkin Lymphoma

Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.

Regeneron Pharmaceuticals is conducting a clinical study titled ‘An Open-Label Study to Assess the Anti-Tumor Activity and Safety of REGN1979, an Anti-CD20 x Anti-CD3 Bispecific Antibody, in Patients With Relapsed or Refractory B-cell Non-Hodgkin Lymphoma.’ The study aims to evaluate the effectiveness and safety of odronextamab, an investigational drug, in treating adult patients with B-cell non-Hodgkin lymphoma (B-NHL) who have previously undergone other cancer therapies. This research is significant as it explores a potential new treatment option for a challenging and recurrent form of cancer.

The intervention being tested in this study is odronextamab, a bispecific antibody designed to target and destroy cancer cells. It is administered through intravenous infusion and aims to improve patient outcomes by effectively targeting B-cell malignancies.

The study is interventional, with a non-randomized, parallel assignment model across five cohorts. It is open-label, meaning there is no masking, and its primary purpose is treatment. The study focuses on assessing the anti-tumor activity and safety of odronextamab in different B-NHL subtypes.

The study began on November 13, 2019, with an estimated primary completion date yet to be updated. The latest update was submitted on July 14, 2025. These timelines are crucial for tracking the study’s progress and anticipating when results might be available.

The potential market implications of this study are significant for Regeneron Pharmaceuticals. Positive outcomes could enhance the company’s stock performance and investor confidence, especially given the competitive landscape of cancer therapies. Successful results may position Regeneron favorably against competitors in the oncology sector.

The study is ongoing, with further details available on the ClinicalTrials portal.